Literature DB >> 15256425

The Fanconi anemia core complex associates with chromatin during S phase.

Jun Mi1, Gary M Kupfer.   

Abstract

Fanconi anemia (FA) is an autosomal recessive disease marked by bone marrow failure, birth defects, and cancer. The FA proteins FANCA, FANCC, FANCE, FANCF, FANCG, and FANCL participate in a core complex. We previously have shown that several members of this complex bind to chromatin until mitosis and that this binding increases after DNA damage. The purpose of the present study was to determine the dynamics of complex movement between cytoplasm and nuclear compartments. Fluorescent-tagged versions of FANCA, FANCC, and FANCG colocalize in cytoplasm and nucleus, chiefly in chromatin. At the G1-S border, the FA core complex exists as foci on chromatin, progressively diffusing and migrating to the nuclear periphery and becoming completely excluded from condensed chromosomes by mitosis. Chromatin fiber analysis shows FA proteins diffusely staining along chromatin fibers during G1-S and S phase. Treatment with the DNA cross-linker mitomycin C results in a diffusion of foci and increased binding of complex proteins to chromatin, as well as diffuse and increased complex binding to chromatin fibers. These data are consistent with the idea that the FA proteins function at the level of chromatin during S phase to regulate and maintain genomic stability.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15256425     DOI: 10.1182/blood-2004-01-0001

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  23 in total

1.  Phosphorylation of FANCD2 on two novel sites is required for mitomycin C resistance.

Authors:  Gary P H Ho; Steven Margossian; Toshiyasu Taniguchi; Alan D D'Andrea
Journal:  Mol Cell Biol       Date:  2006-09       Impact factor: 4.272

Review 2.  Molecular pathogenesis of Fanconi anemia.

Authors:  Natalie Collins; Gary M Kupfer
Journal:  Int J Hematol       Date:  2005-10       Impact factor: 2.490

3.  Evidence for subcomplexes in the Fanconi anemia pathway.

Authors:  Annette L Medhurst; El Houari Laghmani; Jurgen Steltenpool; Miriam Ferrer; Chantal Fontaine; Jan de Groot; Martin A Rooimans; Rik J Scheper; Amom Ruhikanta Meetei; Weidong Wang; Hans Joenje; Johan P de Winter
Journal:  Blood       Date:  2006-05-23       Impact factor: 22.113

4.  UBE2T, the Fanconi anemia core complex, and FANCD2 are recruited independently to chromatin: a basis for the regulation of FANCD2 monoubiquitination.

Authors:  Arno Alpi; Frederic Langevin; Georgina Mosedale; Yuichi J Machida; Anindya Dutta; Ketan J Patel
Journal:  Mol Cell Biol       Date:  2007-10-15       Impact factor: 4.272

5.  Tip60 is required for DNA interstrand cross-link repair in the Fanconi anemia pathway.

Authors:  James Hejna; Megan Holtorf; Jennie Hines; Lauren Mathewson; Aaron Hemphill; Muhsen Al-Dhalimy; Susan B Olson; Robb E Moses
Journal:  J Biol Chem       Date:  2008-02-08       Impact factor: 5.157

Review 6.  Mechanisms of DNA damage, repair, and mutagenesis.

Authors:  Nimrat Chatterjee; Graham C Walker
Journal:  Environ Mol Mutagen       Date:  2017-05-09       Impact factor: 3.216

7.  FANCI protein binds to DNA and interacts with FANCD2 to recognize branched structures.

Authors:  Fenghua Yuan; Jimmy El Hokayem; Wen Zhou; Yanbin Zhang
Journal:  J Biol Chem       Date:  2009-06-27       Impact factor: 5.157

Review 8.  Cellular and molecular consequences of defective Fanconi anemia proteins in replication-coupled DNA repair: mechanistic insights.

Authors:  Larry H Thompson; John M Hinz
Journal:  Mutat Res       Date:  2009-02-21       Impact factor: 2.433

9.  Fanconi anemia proteins stabilize replication forks.

Authors:  Lily Chien Wang; Stacie Stone; Maureen Elizabeth Hoatlin; Jean Gautier
Journal:  DNA Repair (Amst)       Date:  2008-09-25

10.  Functional interaction between the Fanconi Anemia D2 protein and proliferating cell nuclear antigen (PCNA) via a conserved putative PCNA interaction motif.

Authors:  Niall G Howlett; Julie A Harney; Meghan A Rego; Frederick W Kolling; Thomas W Glover
Journal:  J Biol Chem       Date:  2009-08-24       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.